About

Marc Klapholz, MD, FACC, FSCAI is Professor & Chair of the Department of Medicine and Chief of Service at Rutgers - New Jersey Medical School. He also serves as the Director of the Heart Failure Prevention and Treatment Program. Dr. Klapholz received his medical degree from the Albert Einstein College of Medicine and completed his residency in internal medicine, along with an NIH sponsored Heart Failure Research Fellowship, General Cardiology, and Interventional Cardiology Fellowship at the same institution. He is board-certified in Internal Medicine, Cardiovascular Disease, Echocardiography, Interventional Cardiology, and Heart Failure & Transplant. His major research interests include the evaluation of novel therapeutic agents and devices for the treatment of heart failure. Dr. Klapholz has been a principal investigator on over 100 clinical trials in heart failure and other cardiovascular diseases, and he serves on various committees related to heart failure research and guidelines. He has authored numerous articles, book chapters, and reviews in cardiovascular disease, contributing significantly to the field.

Research topics

• Political Science
• Internal medicine
• Medicine
• Cardiology
• Psychiatry
• Pathology

Selected publications

• PERCUTANEOUS MECHANICAL ASPIRATION OF CATHETER ASSOCIATED THROMBUS/ VEGETATIONS IN THE VENA CAVA: A CASE SERIES

  Journal of the American College of Cardiology · 2025-03-29

  articleSenior author
  PublisherDOI

• DON’T BE RASH, ALWAYS CONSIDER BRASH SYNDROME

  Journal of the American College of Cardiology · 2025-03-29 · 1 citations

  articleOpen accessSenior author
  PublisherDOI

• ASSESSMENT OF THE ETIOLOGY OF CIRRHOSIS AND MELD 3.0 SCORES ON PRESENCE AND SEVERITY OF DIASTOLIC DYSFUNCTION IN LIVER TRANSPLANT PATIENTS

  Journal of the American College of Cardiology · 2025-03-29

  articleOpen accessSenior author
  PublisherDOI

• Successful Percutaneous Coronary Stenting in End-Stage Liver Disease Patients Awaiting Liver Transplantation

  Cureus · 2024-12-28

  articleOpen accessSenior author

  Coronary artery disease (CAD) is associated with poor outcomes after orthotopic liver transplantation (OLT). We report on six high-risk end-stage liver disease (ESLD) patients who underwent percutaneous coronary intervention (PCI) with bare metal stents during the preoperative evaluation process. There was no mortality or major adverse cardiac event (MACE) within 90 days of OLT. These patients had advanced models for end-stage liver disease sodium (MELD-Na) scores (mean 24.5), thrombocytopenia (mean 70,500 µL⁻¹), and elevated international normalized ratio (INR; mean 2.0), who tolerated stent implantation followed by modified antiplatelet regimens. Percutaneous coronary intervention may facilitate listing with good OLT outcomes.

  PublisherOA PDFDOI

• Migration of Hepatocellular Carcinoma Into the Right Atrium

  JACC Case Reports · 2024-12-01

  articleOpen access

  A 40-year-old man with a medical history of hepatitis B presented with abdominal distention and leg swelling. A computed tomography scan of the abdomen revealed cirrhosis and a large mass extending from the liver into the inferior vena cava and extending into the right atrium. A transthoracic echocardiogram revealed a large right atrial mass extending from the inferior vena cava with possible attachment to the interatrial septum. The patient was eventually determined to have advanced hepatocellular carcinoma with invasion into the inferior vena cava and into the right atrium, along with pulmonary metastases.

  PublisherDOI

• REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic <i>LMNA</i> -Related Dilated Cardiomyopathy

  Circulation Heart Failure · 2024 · 22 citations

  • Political Science
  • Internal medicine
  • Medicine

  BACKGROUND: )-related dilated cardiomyopathy is a rare genetic cause of heart failure. In a phase 2 trial and long-term extension, the selective p38α MAPK (mitogen-activated protein kinase) inhibitor, ARRY-371797 (PF-07265803), was associated with an improved 6-minute walk test at 12 weeks, which was preserved over 144 weeks. METHODS: variants, New York Heart Association class II/III symptoms, left ventricular ejection fraction ≤50%, implanted cardioverter-defibrillator, and reduced 6-minute walk test distance were randomized to ARRY-371797 400 mg twice daily or placebo. The primary outcome was a change from baseline at week 24 in the 6-minute walk test distance using stratified Hodges-Lehmann estimation and the van Elteren test. Secondary outcomes using similar methodology included change from baseline at week 24 in the Kansas City Cardiomyopathy Questionnaire-physical limitation and total symptom scores, and NT-proBNP (N-terminal pro-B-type natriuretic peptide) concentration. Time to a composite outcome of worsening heart failure or all-cause mortality and overall survival were evaluated using Kaplan-Meier and Cox proportional hazards analyses. RESULTS: =0.84) were similar between groups. No new safety findings were observed. CONCLUSIONS: -related dilated cardiomyopathy. REGISTRATION: URL: https://classic.clinicaltrials.gov; Unique Identifiers: NCT03439514, NCT02057341, and NCT02351856.

  PublisherDOI

• THE ANGIOVAC© SYSTEM FOR DEBULKING RIGHT-SIDED INTRACARDIAC LESIONS: MORE THAN JUST THROMBUS ASPIRATION

  Journal of the American College of Cardiology · 2024-04-01

  articleSenior author
  PublisherDOI

• IN-STENT RESTENOSIS OF A BARE-METAL STENT IN A PATIENT WITH HEMOPHILIA A

  Journal of the American College of Cardiology · 2022-03-01

  articleSenior author
  PublisherDOI

• Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients

  Open Forum Infectious Diseases · 2021 · 11 citations

  1st authorCorresponding
  • Medicine
  • Internal medicine

  BACKGROUND: The utility of convalescent coronavirus disease 2019 (COVID-19) plasma (CCP) in the current pandemic is not well defined. We sought to evaluate the safety and efficacy of CCP in severely or life threateningly ill COVID-19 patients when matched with a contemporaneous cohort. METHODS: support. Demographic, clinical, and laboratory data were analyzed by univariate and multivariable regression analyses accounting for matched design. RESULTS: = .13, respectively). Stratification by pretransfusion mechanical ventilation status showed no differences between groups. No serious transfusion reactions occurred. CONCLUSIONS: In this short-term matched cohort study, transfusion with CCP was safe and showed a nonsignificant association with study outcomes. Randomized and larger trials to identify appropriate timing and dosing of CCP in COVID-19 are warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04420988.

  PublisherOA PDFDOI

• VARIABLE LEFT VENTRICULAR EJECTION FRACTION ON MULTIGATED RADIONUCLIDE IMAGING ANALYZED BY DIFFERENT SOFTWARE PACKAGES IN PATIENTS WITH CANCER

  Journal of the American College of Cardiology · 2020-03-01

  article
  PublisherDOI

Frequent coauthors

• Alfonso H. Waller

  103 shared

• Edo Kaluski

  SUNY Upstate Medical University

  88 shared

• William T. Abraham

  73 shared

• Inder S. Anand

  University of Minnesota

  52 shared

• Scott M. Wasserman

  McGill University Health Centre

  52 shared

• Dirk J. van Veldhuisen

  University Medical Center Groningen

  52 shared

• Piotr Ponikowski

  Wroclaw Medical University

  52 shared

• James Maher

  49 shared

Education

• B.A.

  Yeshiva University College

  1981

• M.D.

  Albert Einstein College of Medicine

  1986

• Other

  Rutgers Business School

  2015

Awards & honors

• 2024 EJI Physician's Award
• Castle Connolly Top Doctor
• NJ Heart Ball - Researcher of the Year